Interview with Patrick Gilligan: Reflections and Future Insights

In a recent conversation, Patrick Gilligan discussed his initial year at Point32Health and shared his expectations for the rest of 2026. This interview has been shortened for clarity.

Q: What do you believe is central to the current challenges facing the health system?

Answer: Well, it’s been five years since the pandemic, and I think the impact of deferred care has taken longer to recover from than expected. There’s quite a bit of pent-up demand, which health plans are really starting to notice in 2023.

Meanwhile, pharmaceutical costs have surged, both in usage and pricing. New indications are being announced consistently for many specialty and brand-name medications. We now have gene therapy and cell therapy available, which, while effective, are also incredibly costly. So, when selecting a health plan, it’s really important to not only consider its effectiveness but also its affordability for members.

Q: Last year, GLP-1 drugs became notably expensive. Point32Health, similar to other insurers, limited GLP-1 coverage mainly to diabetics. What led to that decision?

Answer: We need to determine product pricing before the year begins. A significant discrepancy in actual costs really highlights how deteriorating the profitability of medical insurance can be.

We didn’t quite anticipate how many prescribers would recommend GLP-1 for weight loss, but it turned out to be far more than we imagined. It’s tough to take benefits away from people; we fully acknowledge that.

Looking back, we recognized this was becoming an affordability issue for those buying directly from us, as well as for employers purchasing for their teams. It simply wasn’t sustainable.

Q: How did members react to these changes?

Answer: Naturally, many members who found success with these medications were quite disheartened. Employers initially questioned whether it was the right move; it’s a challenging situation for everyone involved.

However, with the rise of blockbuster drugs, debates about the timing and rationale for covering these treatments will probably continue. There’s still much we have to learn, and this discussion isn’t over. We—and our competitors—will revisit this topic over time.

Q: Point32Health’s early results were positive, but the CFO mentioned this doesn’t guarantee overall annual surplus or lower costs for members. What are your predictions for the rest of this year?

Answer: We have a clear understanding of the steps taken to achieve these results; GLP-1 played a large part in that.

We’re focusing on minimizing administrative costs and improving efficiency. We have also reinforced our Total Health Care Expenditure Program, which includes utilization management and care management strategies. In some cases, this could involve prior authorizations to ensure care is truly necessary.

This strengthening helps us manage costs better than before. While our CFO is correct that we don’t expect an operating profit by year-end, we view this as a crucial transitional year that can lead us toward future profitability.

Q: How will the end of certain grants through the Massachusetts Health Connector affect Point32Health?

Answer: For us, and unfortunately for the market, this results in a reduction in membership. The state previously had close to universal insurance coverage, but recent policy changes have chipped away at that. Consequently, we, like others, have seen a significant drop in members.

Q: It’s been a challenging year for Point32Health, with notable layoffs. Have you faced layoffs yourself? What are your expectations for the company moving forward?

Answer: I’m not going to specify whether that’s complete or not. We have indeed made significant progress in enhancing our competitiveness. That said, the current environment is very competitive, prompting everyone to find ways to be more efficient.

Part of what we do involves contracting with healthcare providers. We expect the doctors and hospitals who deliver essential care to our patients to also find ways to become more efficient. We are setting an example in that regard.